$0.00
0.00%
Nasdaq, Mon, Sep 28 2026.
ISIN
NL0010872420
Symbol
AFMD

Affimed N.V. Stock price

$0.00
+0.00 0.00% 1M
-0.00 50.00% 6M
+0.00 0.00% YTD
-0.00 90.00% 1Y
-4.90 100.00% 3Y
-60.50 100.00% 5Y
-28.30 100.00% 10Y
-57.00 100.00% 20Y
Nasdaq, Closing price Mon, Sep 28 2026
+0.00 0.00%
ISIN
NL0010872420
Symbol
AFMD
Industry

Is Affimed N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
0.0
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
59.5%
Return on Equity
-183.3%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $2.0m
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -78.8%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
3.8%
Employees
76
Rev per Employee
$120.0k

Affimed N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Affimed N.V. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Affimed N.V. forecast:

Buy
90%
Hold
10%

Financial data from Affimed N.V.

Sep '24
+/-
%
1 1
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
30% 30%
2,148%
- Research and Development Expense 59 59
52% 52%
5,947%
-76 -76
41% 41%
-7,593%
- Depreciation and Amortization 3.89 3.89
10% 10%
389%
EBIT (Operating Income) EBIT -80 -80
39% 39%
-7,981%
Net Profit -80 -80
41% 41%
-7,955%

In millions USD.

Don't miss a Thing! We will send you all news about Affimed N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Head office Netherlands
CEO Mr. Leland
Employees 76
Founded 2000
Website www.affimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today